





## Currently there is an estimated 500,000 patients with a primary immunodeficiency disease in the US alone, and approximately 50,000 more diagnosed each year.<sup>1</sup>

With no cure available to address their needs, patients are limited to two treatment options - regular Subcutaneous (SC) or Intravenous (IV) infusions of immunoglobulin. So which is the ideal option?

While both options are proven to support successful, long-term treatments, a host of independent research has highlighted the clear advantages of SC over IV - and several case studies using KORU infusion systems have validated these findings.<sup>2,3</sup>

### HERE ARE THE SCIG FACTS:

- It's proven to reduce systemic reactions.<sup>2</sup>
- It's proven to provide a more consistent drug levels over time, which is linked to less systemic side effects<sup>2</sup> and may increase overall well being.<sup>3</sup>
- It offers patients more flexibility it can be safely administered at home and on their schedule giving patients the ability to live life to the fullest without being tied down to regular on-site treatment appointments.
- It reduces the number of nurse visits and increases patient autonomy since SCIg can be self administered once the patient is properly trained.

#### **EXPLORE THE RESEARCH!**

- 1 National Institute of Allergy and Infectious Diseases *Primary Immune Deficiency Diseases (PIDDs)* www.niaid.nih.gov/diseases-conditions/primary-immune-deficiency-diseases-pidds Accessed November 4, 2021.
- 2 Gardulf A et al. Lancet. 1991; 338:162-166
- 3 Berger M. et al. J Clin Immunol. 2004; 112:1-7
- 4 Latysheva E et al. Immunotherapy. 2020;12: 299-309

### WHY PARTNER WITH KORU FOR SCIG INFUSION SUPPORT?

KORU offers a variety of unique advantages for you and your patients.

- ✓ **Expertise** An industry leader with more than 30 years of proven results
- ✓ Reliability Technology supports more than 1.5 infusions annually
- √ Support Tested training resources for patient and clinicians available live and on-demand
- ✓ Convenience Simple, easy to use and portable systems support patient independence
- ✓ **Results** FDA cleared as a complete system and preferred by patients and clinicians<sup>4</sup>



## **ABOUT KORU FREEDOM INFUSION SYSTEMS**


### PATENTED DESIGNS, OPTIMAL RESULTS

Our complete Freedom infusion systems consist of an infusion pump, tubing and needles.




# FREEDOM60® Syringe Infusion System

The FREEDOM60 supports a 50 ml syringe and is commonly used for larger dosages with one or more syringes.



Wind  $\frac{2}{2}$  Load  $\frac{3}{3}$  Go





Convenient, easy-to-use technology - The KORU Freedom infusion pumps are simple and ready to use in just three simple steps which have been shown to be easily managed, even for those with dexterity issues.



The FreedomEdge supports 20 and 30 ml syringes and is commonly used for smaller dosages with one or more syringes.












### Responsive, balanced infusions

Our syringe drivers feature our trademarked DynEQ® (Dynamic Equilibrium) technology which was developed to automatically respond to tissue over-saturation by slowing down the infusion in real time. This is designed to avoid excessive site reactions, especially IG leakage at needle insertion site which commonly leads to irritation and redness.

### CUSTOMIZATION TO FIT A VARIETY OF PATIENT NEEDS

Available in a variety of sizes to support a range of patients, KORU Precision Flow Rate Tubing™ and the HIgH-Flo SubQ Needle Sets are designed and proven to support subcutaneous infusions.¹





# AT KORU, WE REMAIN COMMITTED TO ENHANCING OUTCOMES FOR YOU AND YOUR PATIENTS.

With years of experience and expertise in the industry, KORU is the ideal partner to ensure effective infusions.

#### Only KORU offers:

- ✓ Decades of insights and success from millions of infusions
- ✓ Multiple global regulatory clearances
- ✓ On-demand, 24/7 training support
- ✓ Innovation backed by constant patient and professional insights
- Commitment to pioneering research in infusion treatments

## CONTACT US TODAY TO DISCOVER HOW PARTNERING WITH KORU CAN SUPPORT YOUR SUCCESS!



Sales and Support Alicia Smith Senior Account Executive asmith@korumedical.com



**Business Development**Brian Hertzog

Vice President of Business Development bhertzog@korumedical.com

1 Latysheva E et al. Immunotherapy. 2020;12: 299-309



KORU Medical Systems | 845-469-2042 | korumedical.com | @korumedical